Archaeal glycolipid adjuvanted vaccines induce strong influenza-specific immune responses through direct immunization in young and aged mice or through passive maternal immunization

Stark, Felicity C.; Akache, Bassel; Ponce, Amalia; Dudani, Renu; Deschatelets, Lise; Jia, Yimei; Sauvageau, Janelle; Williams, Dean T.; Jamshidi, Mohammad P.; Agbayani, Gerard; Wachholz, Kristina; Harrison, Blair A.; Li, Xuguang; Krishnan, Lakshmi; Chen, Wangxue; McCluskie, Michael J.

doi:10.1016/j.vaccine.2019.07.010

Cited by 28 publications

(48 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most recently, we compared different archaeosome vaccine formulations and discovered that admixing antigen and archaeosomes induced similar or superior immune responses to an encapsulated formulation [26]. In a prophylactic vaccination influenza challenge model, we compared formulations that were composed of empty archaeosomes admixed with antigen with the conventional antigen entrapped archaeosomes and again observed comparable immune responses as well as similar protection from the influenza challenge [11]. While it was initially thought that entrapment of antigen within the archaeosome vesicle would enhance cytotoxic CD8 + T cell responses by delivering the antigen to the cytosol, allowing it to readily access MHC class I processing machinery that is necessary to initiate CD8 + T cell responses, these findings indicate that the inherent adjuvant effect of archaeosomes is sufficient to initiate CD8 + T cell responses towards exogenous antigens.…”

Section: Discussionmentioning

confidence: 92%

“…With a goal to advance archaeosome vaccine formulations and improve consistency of formulation and ease of use, the archaeosome lipid composition has evolved from being composed of total polar lipids derived from M. smithii to a single glycolipid, SLA. We have shown, in previous studies, that both lipid formulations are capable of inducing comparable immune responses to numerous antigens [11,18,23]. Most recently, we compared different archaeosome vaccine formulations and discovered that admixing antigen and archaeosomes induced similar or superior immune responses to an encapsulated formulation [26].…”

Section: Discussionmentioning

confidence: 93%

“…Archaeal lipid adjuvants are a good potential candidate for use in combination with CPI's, as evidenced by their proven safety and efficacy in mice [19,44]. In multiple pre-clinical studies, they have been shown to activate antigen-specific CD8 + T cell responses [15,19,26,27] and generate protective immunity in tumor models, e.g., B16-OVA melanoma [7,13,19,23,26,27], and against multiple infectious diseases, e.g., H1N1 influenza [11], Listeria monocytogenes [7,12], Trypanosoma cruzi [13] and Mycobacterium tuberculosis [14]. When compared to commonly used commercial adjuvants, such as Poly(I:C) or Montanide, archaeal lipid vaccines were found to elicit equal or greater antigen specific CD8 + T cell-mediated cytotoxicity and IgG responses [10].…”

Section: Discussionmentioning

confidence: 99%

“…Archaeosomes have been consistently proven to be a versatile adjuvant capable of inducing potent immunity in a number of animal models of disease. To date, archaeosomes have been used with multiple antigens, including listeriolysin (LLO), tyrosinase-related-protein-2 (Trp2), glycoprotein-100 (Gp100), Hepatitis-B surface antigen (HBsAg), influenza haemagglutinin (HA) and Hepatitis-C virus E1E2 heterodimer (HCV E1E2) [7][8][9][10][11][12], inducing both strong antibody responses as well as potent cellular responses that afford protection against infections and/or tumor challenge in murine models [7,8,[12][13][14][15]. Archaeosomes are lipid vesicles composed of glycerolipids derived from archaea.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Simplified Admix Archaeal Glycolipid Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Enhances Protection from Murine Melanoma

et al. 2019

Self Cite

View full text Add to dashboard Cite

Archaeosomes are liposomes composed of natural or synthetic archaeal lipids that when used as adjuvants induce strong long-lasting humoral and cell-mediated immune responses against entrapped antigens. However, traditional entrapped archaeosome formulations have only low entrapment efficiency, therefore we have developed a novel admixed formulation which offers many advantages, including reduced loss of antigen, consistency of batch-to-batch production as well as providing the option to formulate the vaccine immediately before use, which is beneficial for next generation cancer therapy platforms that include patient specific neo-antigens or for use with antigens that are less stable. Herein, we demonstrate that, when used in combination with anti-CTLA-4 and anti-PD-1 checkpoint therapy, this novel admixed archaeosome formulation, comprised of preformed sulfated lactosyl archaeol (SLA) archaeosomes admixed with OVA antigen (SLA–OVA (adm)), was as effective at inducing strong CD8+ T cell responses and protection from a B16-OVA melanoma tumor challenge as the traditionally formulated archaeosomes with encapsulated OVA protein. Furthermore, archaeosome vaccine formulations combined with anti-CTLA-4 and anti-PD-1 therapy, induced OVA-CD8+ T cells within the tumor and immunohistochemical analysis revealed the presence of CD8+ T cells associated with dying or dead tumor cells as well as within or around tumor blood vessels. Overall, archaeosomes constitute an attractive option for use with combinatorial checkpoint inhibitor cancer therapy platforms.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Simplified Admix Archaeal Glycolipid Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Enhances Protection from Murine Melanoma

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Likewise, it is unknown whether superior immune responses would be obtained with other commercially approved adjuvants such as AS01™ and AS04™ if incorporated in an E1/E2-based vaccine. SLA-based adjuvants enhance the generation of antigen-specific immune responses through increased local cytokine production, immune cell trafficking, and antigen uptake at the injection site, leading to increased protection in murine models of infectious disease (e.g., influenza virus) and cancer [10,14,19,20,30]. In previous studies, an encapsulated SLA-based formulation was able to enhance E1/E2-specific cellular responses but did not significantly enhance antibody-mediated HCVpp neutralization [13].…”

Section: Discussionmentioning

confidence: 99%

Effect of Different Adjuvants on the Longevity and Strength of Humoral and Cellular Immune Responses to the HCV Envelope Glycoproteins

et al. 2019

Self Cite

View full text Add to dashboard Cite

Infection by Hepatitis C virus (HCV) can lead to liver cirrhosis/hepatocellular carcinoma and remains a major cause of serious disease morbidity and mortality worldwide. However, current treatment regimens remain inaccessible to most patients, particularly in developing countries, and, therefore, the development of a novel vaccine capable of protecting subjects from chronic infection by HCV could greatly reduce the rates of HCV infection, subsequent liver pathogenesis, and in some cases death. Herein, we evaluated two different semi-synthetic archaeosome formulations as an adjuvant to the E1/E2 HCV envelope protein in a murine model and compared antigen-specific humoral (levels of anti-E1/E2 IgG and HCV pseudoparticle neutralization) and cellular responses (numbers of antigen-specific cytokine-producing T cells) to those generated with adjuvant formulations composed of mimetics of commercial adjuvants including a squalene oil-in-water emulsion, aluminum hydroxide/monophosphoryl lipid A (MPLA) and liposome/MPLA/QS-21. In addition, we measured the longevity of these responses, tracking humoral, and cellular responses up to 6 months following vaccination. Overall, we show that the strength and longevity of anti-HCV responses can be influenced by adjuvant selection. In particular, a simple admixed sulfated S-lactosylarchaeol (SLA) archaeosome formulation generated strong levels of HCV neutralizing antibodies and polyfunctional antigen-specific CD4 T cells producing multiple cytokines such as IFN-γ, TNF-α, and IL-2. While liposome/MPLA/QS-21 as adjuvant generated superior cellular responses, the SLA E1/E2 admixed formulation was superior or equivalent to the other tested formulations in all immune parameters tested.

show abstract

Intranasal administration of unadjuvanted SARS‐CoV‐2 spike antigen boosts antigen‐specific immune responses induced by parenteral protein subunit vaccine prime in mice and hamsters

Agbayani,

Akache,

Renner

et al. 2024

Eur J Immunol

Self Cite

View full text Add to dashboard Cite

With the continued transmission of SARS‐CoV‐2 across widely vaccinated populations, it remains important to develop new vaccines and vaccination strategies capable of providing protective immunity and limiting the spread of disease. Heterologous prime‐boost vaccination based on the selection of different vaccine formulations and administration routes for priming and booster doses presents a promising strategy for inducing broader immune responses in key systemic and respiratory mucosal compartments. Intranasal vaccination can induce mucosal immune responses at the site of SARS‐CoV‐2 infection; however, the lack of clinically approved mucosal adjuvants makes it difficult to induce robust immune responses with protein subunit vaccines. Herein, we evaluated the immunogenicity of heterologous prime‐boost regimens in mice and hamsters based on a parenteral vaccination of the antigen in combination with sulfated lactosylarchaeol (SLA) archaeosomes, a liposome adjuvant comprised of a single semisynthetic archaeal lipid, followed by an intranasally administered unadjuvanted SARS‐CoV‐2 spike antigen. Intranasal administration of unadjuvanted spike to mice and hamsters increased serum spike‐specific IgG titers and spike‐neutralizing activity compared with nonboosted animals. Spike‐specific IgA responses were also detected in the bronchoalveolar lavage fluid in the lungs of mice that received an intranasal boost. In hamsters, the intranasal boost showed high efficacy against SARS‐CoV‐2 infection by protecting from body weight loss and reducing viral titers in the lungs and nasal turbinate. Overall, our heterologous intramuscular prime‐intranasal boost with SLA‐adjuvanted and unadjuvanted spike, respectively, demonstrated the potential of protein subunit formulations to promote antigen‐specific systemic and mucosal immune responses.

show abstract

Archaeal glycolipid adjuvanted vaccines induce strong influenza-specific immune responses through direct immunization in young and aged mice or through passive maternal immunization

Cited by 28 publications

References 42 publications

Simplified Admix Archaeal Glycolipid Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Enhances Protection from Murine Melanoma

Simplified Admix Archaeal Glycolipid Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Enhances Protection from Murine Melanoma

Effect of Different Adjuvants on the Longevity and Strength of Humoral and Cellular Immune Responses to the HCV Envelope Glycoproteins

Intranasal administration of unadjuvanted SARS‐CoV‐2 spike antigen boosts antigen‐specific immune responses induced by parenteral protein subunit vaccine prime in mice and hamsters

Contact Info

Product

Resources

About